Development of Antisense Therapeutics: Implications for Cancer Gene Therapy
- 1 May 1994
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 716 (1), 228-241
- https://doi.org/10.1111/j.1749-6632.1994.tb21715.x
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cellsBiochemistry, 1993
- Role for c-myc in Activation-Induced Apoptotic Cell Death in T Cell HybridomasScience, 1992
- Phosphorothioate oligodeoxynucleotides—anti-sense inhibitors of gene expression?Pharmacology & Therapeutics, 1991
- Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense OligonucleotideLeukemia & Lymphoma, 1990
- G 1 /S Transition in Normal Human T-Lymphocytes Requires the Nuclear Protein Encoded by c- mybScience, 1989
- A c- myb Antisense Oligodeoxynucleotide Inhibits Normal Human Hematopoiesis in VitroScience, 1988
- Expression of Deoxyadenosine and Deoxyguanosine Toxicity at Different Stages of Lymphocyte ActivationScandinavian Journal of Immunology, 1988
- Inhibition of Cellular Proliferation by Antisense Oligodeoxynucleotides to PCNA CyclinScience, 1988
- A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1Nature, 1987
- Differential metabolism of deoxyribonucleosides by leukaemic T cells of immature and mature phenotypeBritish Journal of Haematology, 1985